Table 3.
Outcomes of the subgroup analyses/main study comparing SGLT-2 inhibitors VS placebo in patients with T2DM and HF.
| Study | Intervention | CV death or HHF, n | CV death, n | HHF, n | All caused mortality, n |
|---|---|---|---|---|---|
| CANVAS│ | Canagliflozin | 35.4 | 24.3 | 14.1 | 29.2 |
| Placebo | 56.8 | 31.6 | 28.1 | 38.7 | |
| DAPA-HF | Dapagliflozin | 213/328* | 121 | 138 | 143 |
| Placebo | 268/415* | 148 | 172 | 178 | |
| DECLARE–TIMI 58 | Dapagliflozin | 59/151# | 25/79# | 41/92# | 38/122# |
| Placebo | 95/194# | 47/85# | 63/130# | 68/149# | |
| EMPEROR-Reduced | Empagliflozin | 200 | 104 | 140/221^ | NR |
| Placebo | 265 | 113 | 201/337^ | NR | |
| SOLOIST-WHF | Sotagliflozin | 245 | 51 | 194 | 65 |
| Placebo | 355 | 58 | 297 | 76 |
T2DM, type 2 diabetes mellitus; HF, heart failure; NR, not reported.
*CV death or HHF/CV death or first and recurrent HHF.
#Existing HF only/Combined existing HF and with history of HF.
^Time to first HHF/first and recurrent HHF.
│Data were presented with the unit Patients per 1000 patients-years.